Skip to content

Pfizer Will Dominate $20 Billion Covid-Pill Market in 2022, Analysis Shows

Large-scale generic-drug production likely won’t come until 2023, data firm says

Video player cover image
Pfizer Covid Pill Stops Unvaccinated Hospitalizations
Updated on

Pfizer Inc. is set to dominate a $20 billion market for Covid pills next year as richer nations rush to purchase supplies, while less affluent countries will have to wait until early 2023 for generic-drug companies to produce large quantities, an analysis shows.

Pfizer, already pulling in huge profits from its Covid vaccine, is expected to reap about $17 billion from sales of its experimental therapy, Paxlovid, in 2022, according to Airfinity Ltd. Merck & Co.’s molnupiravir will see about $2.5 billion in revenue next year, the London-based data company said.